Loading clinical trials...
Loading clinical trials...
A Phase 1, Subjects- and Investigator-Blinded, Sponsor-Unblinded, Placebo-Controlled, Randomized, Sequential Cohort Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous and Subcutaneous Doses of DS-7011a in Healthy Subjects
Conditions
Interventions
DS-7011a
Placebo
Locations
2
United States
Apex Clinical Research (Collaborative Neuroscience Research)
Long Beach, California, United States
Worldwide Clinical Trials
San Antonio, Texas, United States
Start Date
February 2, 2022
Primary Completion Date
January 25, 2023
Completion Date
March 22, 2023
Last Updated
April 11, 2023
NCT06875960
NCT06335979
NCT06647069
NCT07371468
NCT05843643
NCT06333483
Lead Sponsor
Daiichi Sankyo
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions